Characteristics | Mean (range) | Frequency studies/patients (%) |
---|---|---|
Sample size | 59 (range:10–206) |  |
Age (years) | 67.5 ± 2.9 (47–90) |  |
Follow-up (months) [n] | 16 ± 15 (1–63) |  |
Continent | Â | Â |
Europe | Â | 13 (50%) |
America | Â | 6 (23%) |
Asia | Â | 3 (11.5%) |
Australia | Â | 3 (11.5%) |
Africa | Â | 1 (4%) |
Studies in languages other than English | Â | 3 (11.5%) |
Type of study | Â | Â |
Design | Â | Â |
   Prospective |  | 24 (92%) |
   Retrospective |  | 1 (4%) |
   Unknown |  | 1 (4%) |
Single-center | Â | 17 (65.4%) |
Multicenter | Â | 9 (34.6%) |
Type of anesthesia | Â | Â |
Local | Â | 3 (13%) |
Local+sedation | Â | 10 (43.5%) |
Spinal | Â | 3 (13%) |
General | Â | 2 (8.7%) |
General/local+sedation | Â | 5 (22%) |
Variables assessed | Â | Â |
Symptoms | Â | 25 (96.2%) |
Quality of life score | Â | 22 (84.6%) |
Qmax (mL/s) | Â | 25 (96.2%) |
PVR (mL) | Â | 17 (65.4%) |
Sexual function | Â | 12 (46.2%) |
Pressure-flow studies | Â | 7 (26.9%) |
Prostatic size | Â | 13 (50%) |
Re-treatment | Â | 17 (65.4%) |
Adverse effects | Â | 22 (84.6%) |
Duration of procedure | Â | 15 (57.7%) |
Hospital stay | Â | 11 (42.3%) |
Quality assessment | Â | Â |
   Consecutive or representative sample |  | Yes: 21 No: 3 Not reported:2 |
   Presence of cointerventions |  | Yes: 19 No: 1 Not reported:6 |
   Evaluation blind or independent |  | Yes: 0 No: 26 Not reported:0 |
   Losses to follow-up ≥ 20% |  | Yes:11 No:9 Not reported:6 |